Winners of the BNA Credibility Prizes 2024
17th April 2024
Job Details
Developing new treatments that can prevent the onset of dementia or protect neurons from damage is hindered by our lack of knowledge in the fundamental causes and mechanisms behind neurodegeneration. Scientists at the UK DRI at Cambridge use cutting-edge approaches to build our understanding of the biological processes behind the earliest stages of neurodegeneration and ageing. They explore mechanisms causing the loss of vital connections between neurons and the pathways that drive repair of these connections, which are essential for memory formation and survival of brain cells and identify key molecular targets for translation into effective treatments to stop, slow or reverse dementia.
The focus of the Metzakopian lab is on insights into novel neuroprotective mechanisms in neurodegeneration that provide new targets for treatments of these disorders. This will involve planning, performing and evaluating experiments to generate targeted human induced pluripotent stem (iPS) cells, optimisation of CRISPR-Cas9 in iPS cell-derived cortical neural progenitors and mature neurons, and development of robust cellular assays.
This project is funded by OpenTargets and will involve collaborations with scientists at the nearby Wellcome Sanger and European Bioinformatics Institutes and the partner organisations GSK, Biogen, Takeda, Cellgene Sanofi.
Requirements
Graduate qualification (or equivalent) in Biological Sciences is required. Experience of core molecular and cell biology techniques is essential, although training in all relevant techniques will be provided. Additionally, experience in mammalian cell culture is necessary.
How to apply
http://www.jobs.cam.ac.uk/job/26255/
Contact details